Intensified Doxorubicin-Based Regimen Efficacy in Residual Non-Hodgkin's Lymphoma Disease: Towards a Computationally Supported Treatment Improvement (Q2788513): Difference between revisions

From MaRDI portal
Set OpenAlex properties.
ReferenceBot (talk | contribs)
Changed an Item
 
Property / cites work
 
Property / cites work: Hopf point analysis for angiogenesis models / rank
 
Normal rank
Property / cites work
 
Property / cites work: Reduction of cytotoxicity to normal tissues by new regimens of cell-cycle phase-specific drugs / rank
 
Normal rank
Property / cites work
 
Property / cites work: Growth of nonnecrotic tumors in the presence and absence of inhibitors / rank
 
Normal rank
Property / cites work
 
Property / cites work: Growth of necrotic tumors in the presence and absence of inhibitors / rank
 
Normal rank
Property / cites work
 
Property / cites work: A theoretical analysis of interval drug dosing for cell-cycle-phase- specific drugs / rank
 
Normal rank
Property / cites work
 
Property / cites work: Q3727300 / rank
 
Normal rank
Property / cites work
 
Property / cites work: Q3809172 / rank
 
Normal rank
Property / cites work
 
Property / cites work: A mathematical model of vascular tumour growth and invasion / rank
 
Normal rank
Property / cites work
 
Property / cites work: A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin's lymphoma: investigation of the current protocol through theoretical modelling results / rank
 
Normal rank
Property / cites work
 
Property / cites work: Improving Cancer Therapy by Doxorubicin and Granulocyte Colony-Stimulating Factor: Insights from a Computerized Model of Human Granulopoiesis / rank
 
Normal rank

Latest revision as of 11:47, 11 July 2024

scientific article
Language Label Description Also known as
English
Intensified Doxorubicin-Based Regimen Efficacy in Residual Non-Hodgkin's Lymphoma Disease: Towards a Computationally Supported Treatment Improvement
scientific article

    Statements

    Intensified Doxorubicin-Based Regimen Efficacy in Residual Non-Hodgkin's Lymphoma Disease: Towards a Computationally Supported Treatment Improvement (English)
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    19 February 2016
    0 references
    0 references
    mathematical model
    0 references
    vascular tumour
    0 references
    avascular tumour
    0 references
    heterogeneity
    0 references
    chemotherapy
    0 references
    non-Hodgkin lymphoma
    0 references
    CHOP
    0 references
    doxorubicin
    0 references
    hybrid cellular automata
    0 references
    0 references